Status:
COMPLETED
Describing Patient With DME, Their Patient Journey and Disease Progression
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Diabetic Macular Edema
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to characterize patients with diabetic macular edema (DME), their progression, the treatment received and associate the functional and physiological outcomes related to the treatment.
Eligibility Criteria
Inclusion
- All patients ≥18 years, with a DME diagnosis in at least one eye, included in the Vestrum database identified during the study period (January 2015 to April 2023)
Exclusion
- Patients without the information of laterality will be excluded.
Key Trial Info
Start Date :
August 3 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
221004 Patients enrolled
Trial Details
Trial ID
NCT05966753
Start Date
August 3 2023
End Date
December 31 2023
Last Update
December 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CorEvitas HQ
Waltham, Massachusetts, United States, 02451